Panobinostat in combination with bortezomib and dexamethasone in multiply relapsed and refractory myeloma; UK routine care cohort

The combination of panobinostat, bortezomib and dexamethasone (PanBorDex) is available as a treatment option for relapsed refractory multiple myeloma (RRMM) based on the PANORAMA-1 trial which investigated this triplet in early relapse. In routine clinical care, PanBorDex is used primarily in later...

Descripción completa

Detalles Bibliográficos
Autores principales: Maouche, Nadjoua, Kishore, Bhuvan, Bhatti, Zara, Basu, Supratik, Karim, Farheen, Sundararaman, Sharadha, Collings, Freya, Tseu, Bing, Leary, Heather, Ryman, Noel, Reddy, Udaya, Vallance, Grant D., Kothari, Jaimal, Ramasamy, Karthik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9262230/
https://www.ncbi.nlm.nih.gov/pubmed/35797277
http://dx.doi.org/10.1371/journal.pone.0270854

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9262230/
https://www.ncbi.nlm.nih.gov/pubmed/35797277
http://dx.doi.org/10.1371/journal.pone.0270854

Ejemplares similares